Literature DB >> 18818894

[Hereditary thyroid cancer].

H Dralle1, A Machens, K Lorenz.   

Abstract

Hereditary thyroid carcinomas are present in about 5% of differentiated (DTC) and 25% of medullary thyroid carcinomas (MTC). They are part of a multiorgan tumour syndrome (e. g. FAP Gardner's syndrome with DTC and MEN 2 syndrome with MTC) or confined to the thyroid gland. Hereditary thyroid carcinomas typically show multifocal growth and occur in young patients. Due to germ cell mutations as the underlying cause of disease, partial thyroidectomies that may be justified in early sporadic carcinomas are not indicated in this type of tumours. In the case of hereditary DTC, the genetic basis of the disease has been demonstrated only in syndromatic tumour variants. In most nonsyndromatic cases, specific genetic alterations have not yet been identified. In both types of hereditary DTC, prophylactic thyroidectomy is not warranted due to the favourable prognosis of tumours that do not differ from sporadic ones. Point mutations of the RET proto-oncogene have been known for 15 years to be the genetic basis of hereditary MTC. Recently several new mutations were discovered; however, final conclusions regarding their clinical significance are not possible at present. Basically it has been shown that the clinical aggressivity of tumour development follows a genotype-phenotype correlation (risk groups 1-3). However, in mutations of all risk classes there exists a wide spectrum of different stages of hereditary C-cell disease in individual risk groups. Regarding time and extent of prophylactic thyroidectomy (without or with lymph node dissection) a combined molecular-biochemical concept including the use of pentagastrin-stimulated calcitonin values is therefore recommended.

Entities:  

Mesh:

Year:  2008        PMID: 18818894     DOI: 10.1007/s00104-008-1558-y

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  93 in total

1.  Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?

Authors:  S M Baumgartner-Parzer; R Lang; L Wagner; G Heinze; B Niederle; K Kaserer; W Waldhäusl; H Vierhapper
Journal:  J Clin Endocrinol Metab       Date:  2005-08-23       Impact factor: 5.958

2.  Does familial non-medullary thyroid cancer adversely affect survival?

Authors:  Frederic Triponez; Mariwil Wong; Cord Sturgeon; Nadine Caron; David G Ginzinger; Mark R Segal; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

3.  Evaluation of surgical results and prediction of prognosis in patients with medullary thyroid carcinoma by analysis of serum calcitonin levels.

Authors:  A Miyauchi; F Matsuzuka; K Kuma; S Takai; K Nakamoto; K Nakamura; S Nanjo; M Maeda
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

4.  Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer.

Authors:  Mark Sywak; Lachlan Cornford; Paul Roach; Peter Stalberg; Stan Sidhu; Leigh Delbridge
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

Review 5.  Familial nonmedullary thyroid neoplasia.

Authors:  H Rubén Harach
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation.

Authors:  Andreas Machens; Ulrich Schneyer; Hans-Jürgen Holzhausen; Friedhelm Raue; Henning Dralle
Journal:  Surgery       Date:  2004-11       Impact factor: 3.982

7.  Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds.

Authors:  S Dvorakova; E Vaclavikova; A Ryska; J Cap; P Vlcek; J Duskova; D Kodetova; V Holub; Z Novak; B Bendlova
Journal:  Exp Clin Endocrinol Diabetes       Date:  2006-04       Impact factor: 2.949

8.  Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid.

Authors:  E D Williams; C L Brown; I Doniach
Journal:  J Clin Pathol       Date:  1966-03       Impact factor: 3.411

Review 9.  Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma.

Authors:  Andreas Machens; Henning Dralle
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

10.  A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.

Authors:  Adriana M Alvares Da Silva; Rui M B Maciel; Magnus R Dias Da Silva; Silvia R C Toledo; Marcos B De Carvalho; Janete M Cerutti
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

View more
  5 in total

1.  [Familial thyroid carcinomas].

Authors:  K W Schmid; S Ting; S-Y Sheu
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

Review 2.  [Thyroid C cells and their pathology: Part 2: Medullary thyroid carcinoma].

Authors:  S Synoracki; S T Schmid; S Ting; K W Schmid
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 3.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

4.  [Surgery of thyroid carcinoma].

Authors:  H Dralle; K Lorenz; A Machens
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

5.  One-step nucleic acid amplification testing in medullary thyroid cancer lymph nodes: a case series.

Authors:  Krzysztof Kaczka; Wojciech Fendler; Maciej Borowiec; Wojciech Młynarski; Katarzyna Paduszynska; Anna Grzegory; Lech Pomorski
Journal:  Arch Med Sci       Date:  2015-03-14       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.